Journey Medical (DERM) FCF Margin (2020 - 2026)

Journey Medical has reported FCF Margin for 7 years, with the latest figure at 18.27% in Q1 2026.

• For the quarter ending Q1 2026, FCF Margin rose 3983.0% year-over-year to 18.27%; the trailing twelve-month figure through Mar 2026 stood at 10.46% (up 188.0% YoY), and the FY2025 full-year result was 20.11%, up 2287.0% from the prior year.
• FCF Margin for Q1 2026 stood at 18.27%, up from 39.08% in the prior quarter.
• The five-year high for FCF Margin was 387.61% in Q4 2023, with the low at 91.92% in Q1 2022.
• Historically, FCF Margin has averaged 10.65% across 5 years, with a median of 18.04% in 2022.
• Annual changes were most pronounced in 2023 — FCF Margin soared 40824 bps — and 2024, when it slumped 37128 bps.
• Journey Medical's FCF Margin stood at 20.63% in 2022, then jumped by 1979 bps to 387.61% in 2023, then slumped by 96 bps to 16.34% in 2024, then plunged by 339 bps to 39.08% in 2025, then surged by 147 bps to 18.27% in 2026.
• The last three FCF Margin figures came in at 18.27% (Q1 2026), 39.08% (Q4 2025), and 14.0% (Q3 2025), per Business Quant data.